A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide
Status:
Completed
Trial end date:
2019-03-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of short-term treatment with darolutamide
on breast cancer cells (i.e., how the treatment may change the genes or proteins in breast
cancer cells) and to evaluate its safety and the way it is tolerated by subjects.
The intent is to study these changes in order to have a better understanding of the potential
use of darolutamide for women with EBC, know which patients are likely or unlikely to respond
to this treatment, and determine how darolutamide may be combined with other anti-cancer
drugs.